All regulations
Nonrulemaking
FDA
FDA-2026-N-3334
Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability
Documents
1
Comments
0
Key Dates
Comment Period OpensApr 24, 2026
Documents
| Type | Title | Status |
|---|---|---|
Notice |
Keywords
2025--651
CBER
CDER
Report on the Performance of
Drug and Biologics Firms in Conducting
Postmarketing Requirements and Commitments
Availability
OPEN
Data from Regulations.gov